Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 03-11-2022 | Myocardial Infarction | Original Article

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling

Authors: Min Zhang, Weiwei Quan, Tianqi Zhu, Shuo Feng, Xinyun Huang, Hongping Meng, Run Du, Zhengbin Zhu, Xuezheng Qu, Ping Li, Yuke Cui, Kuangyu Shi, Xiaoxiang Yan, Ruiyan Zhang, Biao Li

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2023

Abstract

Purpose

To assess predictive value of ⁶⁸Ga-labeled fibroblast activation protein inhibitor-04 ([⁶⁸Ga]Ga-DOTA-FAPI-04) PET/MR for late left ventricular (LV) remodeling in patients with ST-segment elevated myocardial infarction (STEMI).

Methods

Twenty-six patients with STEMI were included in the study. [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR was performed at baseline and at average 12 months after STEMI. LV remodeling was defined as >10% increase in LV end-systolic volume (LVESV) from baseline to 12 months.

Results

The LV remodeling group demonstrated higher [⁶⁸Ga]Ga-DOTA-FAPI-04 uptake volume (UV) at baseline than the non-LV remodeling group (p < 0.001). [⁶⁸Ga]Ga-DOTA-FAPI-04 UV at baseline was a significant predictor (OR = 1.048, p = 0.011) for LV remodeling at 12 months after STEMI. Compared to clinical information, MR imaging and cardiac function parameters at baseline, [⁶⁸Ga]Ga-DOTA-FAPI-04 UV demonstrated better predictive ability (AUC = 0.938, p < 0.001) for late LV remodeling, with sensitivity of 100.0% and specificity of 81.3%.

Conclusions

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR is an effective tool to non-invasively quantify myocardial fibroblasts activation, and baseline [⁶⁸Ga]Ga-DOTA-FAPI-04 UV may have potential predictive value for late LV remodeling.

Available only for authorised users

Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, remodeling, and failing heart. JACC Basic Transl Sci. 2019;4(3):449–67. https://doi.org/10.1016/j.jacbts.2019.02.006.CrossRef

Tillmanns J, Hoffmann D, Habbaba Y, Schmitto JD, Sedding D, Fraccarollo D, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol. 2015;87:194–203. https://doi.org/10.1016/j.yjmcc.2015.08.016.CrossRef

Siebermair J, Kohler MI, Kupusovic J, Nekolla SG, Kessler L, Ferdinandus J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J Nucl Cardiol. 2021;28(3):812–21. https://doi.org/10.1007/s12350-020-02307-w.CrossRef

Wang L, Zhang Z, Zhao Z, Yan C, Fang W. (68)Ga-FAPI right heart uptake in a patient with idiopathic pulmonary arterial hypertension. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02407-7.

Shi X, Lin X, Huo L, Li X. Cardiac fibroblast activation in dilated cardiomyopathy detected by positron emission tomography. J Nucl Cardiol. 2020. https://doi.org/10.1007/s12350-020-02315-w.

Heckmann MB, Reinhardt F, Finke D, Katus HA, Haberkorn U, Leuschner F, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging. 2020;13(9):e010628. https://doi.org/10.1161/CIRCIMAGING.120.010628.CrossRef

Notohamiprodjo S, Nekolla SG, Robu S, Villagran Asiares A, Kupatt C, Ibrahim T, et al. Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using (68)Ga-FAPI-04. J Nucl Cardiol. 2021. https://doi.org/10.1007/s12350-021-02603-z.

Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, et al. Molecular Imaging of fibroblast activity after myocardial infarction using a (68)Ga-Labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med. 2019;60(12):1743–9. https://doi.org/10.2967/jnumed.119.226993.CrossRef

Diekmann J, Koenig T, Zwadlo C, Derlin T, Neuser J, Thackeray JT, et al. Molecular imaging identifies fibroblast activation beyond the infarct region after acute myocardial infarction. J Am Coll Cardiol. 2021;77(14):1835–7. https://doi.org/10.1016/j.jacc.2021.02.019.CrossRef

10.

Kessler L, Kupusovic J, Ferdinandus J, Hirmas N, Umutlu L, Zarrad F, et al. Visualization of fibroblast activation after myocardial infarction using 68Ga-FAPI PET. Clin Nucl Med. 2021;46(10):807–13. https://doi.org/10.1097/RLU.0000000000003745.CrossRef

11.

Xie B, Wang J, Xi XY, Guo X, Chen BX, Li L, et al. Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/s00259-021-05674-9.

12.

Diekmann J, Koenig T, Thackeray JT, Derlin T, Czerner C, Neuser J, et al. Cardiac Fibroblast activation in patients early after acute myocardial infarction: integration with magnetic resonance tissue characterization and subsequent functional outcome. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263555.

13.

Itzahki Ben Zadok O, Ben-Gal T, Abelow A, Shechter A, Zusman O, Iakobishvili Z, et al. Temporal trends in the characteristics, management and outcomes of patients with acute coronary syndrome according to their Killip class. Am J Cardiol. 2019;124(12):1862–8. https://doi.org/10.1016/j.amjcard.2019.09.012.CrossRef

14.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22. https://doi.org/10.2967/jnumed.118.210443.CrossRef

15.

Heiberg E, Sjogren J, Ugander M, Carlsson M, Engblom H, Arheden H. Design and validation of Segment--freely available software for cardiovascular image analysis. BMC Med Imaging. 2010;10:1. https://doi.org/10.1186/1471-2342-10-1.CrossRef

16.

Engblom H, Tufvesson J, Jablonowski R, Carlsson M, Aletras AH, Hoffmann P, et al. A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data. J Cardiovasc Magn Reson. 2016;18(1):27. https://doi.org/10.1186/s12968-016-0242-5.CrossRef

17.

Farah E, Cogni AL, Minicucci MF, Azevedo PS, Okoshi K, Matsubara BB, et al. Prevalence and predictors of ventricular remodeling after anterior myocardial infarction in the era of modern medical therapy. Med Sci Monit. 2012;18(5):CR276–81. https://doi.org/10.12659/msm.882732.CrossRef

18.

Garcia G, Chao de la Barca JM, Mirebeau-Prunier D, Reynier P, Furber A, Prunier F, et al. Metabolomic approach in STEMI-Patients undergoing left ventricular remodeling. Int J Mol Sci. 2019;20(2). https://doi.org/10.3390/ijms20020289.

19.

Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157–72. https://doi.org/10.1002/sim.2929.CrossRef

20.

Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91–112. https://doi.org/10.1161/CIRCRESAHA.116.303577.CrossRef

21.

Ibanez B, Aletras AH, Arai AE, Arheden H, Bax J, Berry C, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;74(2):238–56. https://doi.org/10.1016/j.jacc.2019.05.024.CrossRef

22.

Vazir A, Fox K, Westaby J, Evans MJ, Westaby S. Can we remove scar and fibrosis from adult human myocardium? Eur Heart J. 2019;40(12):960–6. https://doi.org/10.1093/eurheartj/ehy503.CrossRef

23.

Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94(6):730–6. https://doi.org/10.1136/hrt.2007.122622.CrossRef

24.

Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, et al. Relationship Between infarct size and outcomes following primary PCI: Patient-level analysis from 10 randomized trials. J Am Coll Cardiol. 2016;67(14):1674–83. https://doi.org/10.1016/j.jacc.2016.01.069.CrossRef

25.

Ahn KT, Song YB, Choe YH, Yang JH, Hahn JY, Choi JH, et al. Impact of transmural necrosis on left ventricular remodeling and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Int J Cardiovasc Imaging. 2013;29(4):835–42. https://doi.org/10.1007/s10554-012-0155-9.CrossRef

26.

Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol. 2016;67(17):2050–60. https://doi.org/10.1016/j.jacc.2016.01.073.CrossRef

27.

Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161–72. https://doi.org/10.1161/01.cir.81.4.1161.CrossRef

28.

Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–50. https://doi.org/10.1016/j.jacc.2009.08.047.CrossRef

29.

Van Linthout S, Tschope C. Inflammation - cause or consequence of heart failure or both? Curr Heart Fail Rep. 2017;14(4):251–65. https://doi.org/10.1007/s11897-017-0337-9.CrossRef

30.

Scalise RFM, De Sarro R, Caracciolo A, Lauro R, Squadrito F, Carerj S, et al. Fibrosis after myocardial infarction: an overview on cellular processes, molecular pathways, clinical evaluation and prognostic value. Med Sci (Basel). 2021;9(1). https://doi.org/10.3390/medsci9010016.

31.

Yalta K, Yilmaz MB, Yalta T, Palabiyik O, Taylan G, Zorkun C. Late Versus Early Myocardial Remodeling after acute myocardial infarction: a comparative review on mechanistic insights and clinical implications. J Cardiovasc Pharmacol Ther. 2020;25(1):15–26. https://doi.org/10.1177/1074248419869618.CrossRef

Title: [68Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling
Authors: Min Zhang
Weiwei Quan
Tianqi Zhu
Shuo Feng
Xinyun Huang
Hongping Meng
Run Du
Zhengbin Zhu
Xuezheng Qu
Ping Li
Yuke Cui
Kuangyu Shi
Xiaoxiang Yan
Ruiyan Zhang
Biao Li
Publication date: 03-11-2022
Publisher: Springer Berlin Heidelberg
Keyword: Myocardial Infarction
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-06015-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR in patients with acute myocardial infarction: potential role of predicting left ventricular remodeling

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2023

Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

Correction to: Nuclear medicine in the assessment and prevention of cancer therapy‑related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

Predicting clinically significant prostate cancer with a deep learning approach: a multicentre retrospective study

The “complete diagnosis in one day” could be the next goal: the neuro-COVID paradigm

On the factors affecting the liver SUV in [18F]FDG PET/CT imaging

Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics